Latest Regulation News

ADX Energy reports a 17% production dip in Q3 2025 due to well downtime but boosts sales revenue by 23%, while advancing drilling plans and acquiring key infrastructure.

DigitalX Limited has accelerated its Bitcoin-first treasury strategy with a $20.7 million capital raise, nearly doubling its Bitcoin holdings to over 500 BTC and unveiling an ambitious plan to reach 2,100 BTC by 2027.

Alexium International Group reported a 26% rise in Q1 FY26 sales driven by new business wins and expanded foam bedding applications, while navigating tighter funding conditions.

Western Yilgarn NL has significantly boosted its bauxite portfolio with two new JORC-compliant resource estimates and confirmed high-grade gallium and cobalt discoveries, positioning itself strongly in critical minerals and gold exploration.

SRJ Technologies has made significant strides in its three-year growth plan, securing a $6 million joint venture with a Middle East National Oil Company and raising £1.4 million to fund its regional expansion.

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

Argenica Therapeutics reports ARG-007 is safe in acute ischemic stroke patients and shows promising efficacy signals in a high-risk subgroup, paving the way for a focused Phase 2b trial.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

Race Oncology has filed pivotal patents on the active (E,E)-bisantrene isomer, potentially extending its drug exclusivity by two decades, while advancing its Phase 1 clinical trial and maintaining a strong cash position.

Polymetals Resources has reported a fatal underground incident at its Endeavor Mine in NSW, resulting in two deaths and a suspension of operations as investigations proceed.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

Mach7 Technologies reports a pivotal first quarter for FY26, marked by the initial go-live of a major U.S. Veterans Health Administration contract, leadership changes, and a strategic business reset.